Eptifibatide-associated acute, profound thrombocytopenia

Annals of Pharmacotherapy

Volumn 39, Issue 2, 2005, Pages 368-372

  Coons, James C ^a   Barcelona, Robert A ^a,b   Freedy, Tucker ^a   Hagerty, Michael F ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Eptifibatide; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALPHA TOCOPHEROL; ARGATROBAN; CLOPIDOGREL; DIGOXIN; DIPHENHYDRAMINE; DOPAMINE; EPTIFIBATIDE; FELODIPINE; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METHYLPREDNISOLONE; METOPROLOL; MORPHINE; PHENYLEPHRINE; SIMVASTATIN; WARFARIN;

ADULT; AGED; ARTICLE; BACKACHE; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; EYE DISEASE; FEMALE; HEART MUSCLE ISCHEMIA; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; LABORATORY TEST; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PETECHIA; PRIORITY JOURNAL; SHOCK; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; WHEEZING;

ACUTE DISEASE; ADULT; AGED; FEMALE; HUMANS; MALE; PEPTIDES; PLATELET COUNT; THROMBOCYTOPENIA;

EID: 12844266030     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E244     Document Type: Article

References (18)

1. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
2. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-3.
3. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999;138(suppl):S317-26.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
6. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary artery stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-44.
7. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 2001;88:428-31.
8. Yoder M, Edwards RF. Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 2002;36:628-30. DOI 10.1345/aph.1A218
9. Nagge J, Jackevicius C, Dzavik V, Ross JR, Sedelin P. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 2003;23:374-9.
10. Salengro E, Mulvihill NT, Farah B. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Cathet Cardiovasc Intervent 2003;58:73-5.
11. Rezkalla SH, Hayes JJ, Curtis BR, Aster RH. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Cathet Cardiovasc Intervent 2003;58:76-9.
12. Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 2003;1:392-4.
13. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139(suppl):S38-45.
14. Package insert. Reopro (abciximab). Indianapolis: Eli Lilly, November 2003.
15. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-5.
16. Madan M, Tcheng JE. Update on abciximab readministration during percutaneous coronary interventions. Curr Interv Cardiol Rep 2000;2:244-9.
17. Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kubler W, et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999;84:519-24.
18. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GP IIb/IIIa. Blood 2002;100:2071-6.